Biomarkers for the diagnosis of heart failure in people with diabetes: A consensus report from diabetes technology society.

Yeung, Andrea M; Huang, Jingtong; Pandey, Ambarish; Hashim, Ibrahim A; Kerr, David; Pop-Busui, Rodica; Rhee, Connie M; Shah, Viral N; Bally, Lia; Bayes-Genis, Antoni; Bee, Yong Mong; Bergenstal, Richard; Butler, Javed; Fleming, G Alexander; Gilbert, Gregory; Greene, Stephen J; Kosiborod, Mikhail N; Leiter, Lawrence A; Mankovsky, Boris; Martens, Thomas W; ... (2023). Biomarkers for the diagnosis of heart failure in people with diabetes: A consensus report from diabetes technology society. Progress in cardiovascular diseases, 79, pp. 65-79. Elsevier 10.1016/j.pcad.2023.05.002

1-s2.0-S0033062023000506-main.pdf - Accepted Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (1MB) | Preview

Diabetes Technology Society assembled a panel of clinician experts in diabetes, biomarker screening, and heart failure to review the current evidence on biomarker screening of people with diabetes (PWD) for heart failure (HF), who are, by definition, at risk for HF (Stage A HF). This consensus report reviews features of HF in PWD from the perspectives of 1) epidemiology, 2) classification of stages, 3) pathophysiology, 4) biomarkers for diagnosing, 5) biomarker assays, 6) diagnostic accuracy of biomarkers, 7) benefits of biomarker screening, 8) consensus recommendations for biomarker screening, 9) stratification of Stage B HF, 10) echocardiographic screening, 11) management of Stage A and Stage B HF, and 12) future directions. The Diabetes Technology Society panel recommends 1) biomarker screening with one of two circulating natriuretic peptides (B-type natriuretic peptide or N-terminal prohormone of B-type natriuretic peptide), 2) beginning screening five years following diagnosis of type 1 diabetes (T1D) and at the diagnosis of type 2 diabetes (T2D), 3) beginning routine screening no earlier than at age 30 years for T1D (irrespective of age of diagnosis) and at any age for T2D, 4) screening annually, and 5) testing any time of day. The panel also recommends that an abnormal biomarker test defines asymptomatic preclinical HF (Stage B HF). This diagnosis requires follow-up using transthoracic echocardiography for classification into one of four subcategories of Stage B HF, corresponding to risk of progression to symptomatic clinical HF (Stage C HF). These recommendations will allow identification and management of Stage A and Stage B HF in PWD to prevent progression to Stage C HF or advanced HF (Stage D HF).

Item Type:

Journal Article (Review Article)


10 Strategic Research Centers > ARTORG Center for Biomedical Engineering Research
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Endocrinology, Diabetology and Clinical Nutrition

UniBE Contributor:

Bally, Lia Claudia


500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health








Pubmed Import

Date Deposited:

15 May 2023 11:10

Last Modified:

12 May 2024 00:25

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

Biomarkers Diabetes Echocardiogram Heart failure Natriuretic peptides Screening



Actions (login required)

Edit item Edit item
Provide Feedback